Table 3 Most common treatment-related adverse events (Grade ≥ 3).

From: Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer

Adverse Events

Nab-PC (N = 55)

Decetaxel (N = 216)

P* value

Grade ≥ 3

Grade ≥ 3

Hematologic AEs

     Neutropenia

20(36.4%)

121(56.0%)

0.010

     Thrombocytopenia

6(10.9%)

7(3.2%)

0.043

     Anemia

8(14.5%)

4(1.9%)

0.000

Non-hemetologic AEs

     Fatigue

1(1.8%)

6(2.8%)

1.000

     Nausea/Vomiting

4(7.3%)

13(6.0%)

0.975

     Diarrhea

4(7.3%)

19(8.8%)

0.927

     Sensory neuropathy

2(3.6%)

11(5.1%)

0.922

     Myalgia

1(1.8%)

2(0.9%)

0.495

     Arthragia

0(0.0%)

2(0.9%)

1.000

  1. Abbreviations: AEs, Adverse Events;
  2. *P values were generated by compare the incidence of Grade ≥ 3 AEs between the two groups using Chi-square or Fisher’s exact test.
Back to article page